Trilaciclib Dihydrochloride Patent Expiration
Trilaciclib Dihydrochloride is Used for reducing chemotherapy-induced myelosuppression in adult patients receiving specific regimens for extensive-stage small cell lung cancer. It was first introduced by Pharmacosmos As
Trilaciclib Dihydrochloride Patents
Given below is the list of patents protecting Trilaciclib Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cosela | US11529352 | Preservation of immune response during chemotherapy regimens | Jul 23, 2039 | Pharmacosmos |
| Cosela | US10085992 | Transient protection of normal cells during chemotherapy | Mar 14, 2034 | Pharmacosmos |
| Cosela | US10966984 | Transient protection of normal cells during chemotherapy | Mar 14, 2034 | Pharmacosmos |
| Cosela | US11717523 | Transient protection of normal cells during chemotherapy | Mar 14, 2034 | Pharmacosmos |
| Cosela | US9487530 | Transient protection of normal cells during chemotherapy | Mar 14, 2034 | Pharmacosmos |
| Cosela | US10189849 | CDK inhibitors | Oct 25, 2031 | Pharmacosmos |
| Cosela | US10189850 | CDK inhibitors | Oct 25, 2031 | Pharmacosmos |
| Cosela | US10927120 | CDK inhibitors | Oct 25, 2031 | Pharmacosmos |
| Cosela | US11040042 | Transient protection of normal cells during chemotherapy | Oct 25, 2031 | Pharmacosmos |
| Cosela | US8598186 | CDK inhibitors | Oct 25, 2031 | Pharmacosmos |
| Cosela | US8598197 | CDK inhibitors | Oct 25, 2031 | Pharmacosmos |
| Cosela | US9957276 | CDK inhibitors | Oct 25, 2031 | Pharmacosmos |
Trilaciclib Dihydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List